Communications Capital Corporation Announces Investment Opinion On CITA Biomedical.

Business Editors

NOTE TO EDITORS: The following is an investment opinion issued

by CITA Biomedical 

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--May 30, 2000

CITA Biomedical, Inc. (OTCBB:DTOX) announced today that Communications Capital Corporation, an independent equity research firm, has issued a buy recommendation on its stock this morning.

"We recommend the purchase of the shares of CITA Biomedical, Inc. for prospects of above average capital appreciation," said David V. Jackson, CFA, the Marina Del Rey, California-based firm's chief research analyst. "We believe CITA Biomedical is uniquely positioned to treat and detoxify those who suffer from opiate addiction."

In his extensive report, Jackson notes that traditional forms of detoxification typically take from 6 - 28 days, and have a first year success rate of 7-17%. By comparison, he says, CITA Biomedical patients undergo a detoxification process that lasts just four to six hours, with an estimated 60% continuing to be addiction free after one year.

Currently, CITA Biomedical is conducting its detoxification programs in five major metropolitan hospitals, located in Chicago, Los Angeles, Phoenix, Denver and Portland, Oregon. The analyst notes that over the next several years that number is expected to triple.

"With plans to bring the procedure to an additional 10 hospitals, the company intends to expand its scope to treat most addictions, including drugs, behavioral and alcohol, and is researching a vaccine for cocaine," the report continues.

Noting the importance of follow up, Jackson points out that "CITA provides for aftercare through Flexible Intensity Treatment ... and is exploring acquisition candidates in this area."

Looking out over a five-year period to 2004, the report states that if current funding opportunities materialize the company could enjoy substantial growth in total revenues, earnings and income per share.

It anticipates nearly break-even operations in the current year, followed by upwards trends in all leading indicators in the following years. "Based on a 30X price earnings multiple and an EPS estimate of $1.12 we would use a price target of $34 per share by the end of the five year period," the report suggests, projecting 2004 total revenues at more than $52 million.

"However," it continues, "given the size of the total addiction market, CITA's unique opportunity to serve it beyond opiates, and potential acquisition candidates, we believe there could be additional upside price potential."

The report's author, David V. Jackson, has more than 30 years experience with major Wall Street investment banking firms. Early in his career that began with Merrill Lynch he earned the prestigious designation of Chartered Financial Analyst.

At the investment banking firm of Bateman Hill Eichler Richards he rose to the position of Senior Vice President. He then became a Co-Director of Institutional Research and Senior Vice President of Morgan Olmstead Kennedy & Gardner, and a founder of its institutional sales and research department.

He joined H. J. Meyers & Co., Inc. in 1987 as Executive Vice President and a Board member, then co-founded and was managing partner of its Western Group subsidiary, responsible both for due diligence on equity offerings and ongoing research coverage. In 1992, Institutional Investor magazine named Jackson one of its top 10 stock pickers among all analysts in the U.S.

That same year, he founded Communications Capital Corporation as President & CEO, the position he continues in today, while also serving as Managing Director of Research for Capitol Bay Securities.

To receive a complete copy of the research report contact Investor Relations at [phone] or email your request to [e-mail]. A full copy will be available on the website after June 1, 2000 at http://www.citabio.com.

This news release contains forward-looking statements regarding the company and its business. These forward-looking statements are based largely on the company's expectations and are and are subject to a number of risks and uncertainties, some of which are beyond the company's control. The company undertakes no obligation to publicly release the results of any revision to these forward-looking statements that may be made to reflect events or circumstances after the dates hereof or to reflect the occurrence of unanticipated events.